Saouda Christopher, Makke Yamane, Edelberg Helen, Koubeissi Mohamad Z
Department of Neurology, George Washington University, Washington, DC, USA.
Epilepsy Behav Rep. 2025 Jun 27;31:100800. doi: 10.1016/j.ebr.2025.100800. eCollection 2025 Sep.
Cenobamate (CNB) is an antiseizure medication (ASM) approved for the treatment of focal epilepsy. Rash and edema are uncommon adverse effects of this medication. We report two patients with medically refractory epilepsy (MRE) who received CNB and developed chest and facial rash and edema after the initial dose of 12.5 mg/d that prompted discontinuation of the medication with ensuing resolution of the rash and edema. Rechallenging with CNB resulted in similar reactions. Our report aims at increasing awareness of these reactions to CNB.
司替戊醇（CNB）是一种被批准用于治疗局灶性癫痫的抗癫痫药物（ASM）。皮疹和水肿是这种药物不常见的不良反应。我们报告了两名难治性癫痫（MRE）患者，他们接受了司替戊醇治疗，在初始剂量为12.5毫克/天后出现胸部和面部皮疹及水肿，这促使他们停用了该药物，随后皮疹和水肿消退。再次使用司替戊醇导致了类似的反应。我们的报告旨在提高对司替戊醇这些反应的认识。
